Last $25.18 USD
Change Today +0.27 / 1.08%
Volume 1.4M
QGEN On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 8:10 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QGEN) Snapshot

Open
$24.94
Previous Close
$24.91
Day High
$25.31
Day Low
$24.88
52 Week High
07/18/14 - $25.32
52 Week Low
04/15/14 - $19.46
Market Cap
5.8B
Average Volume 10 Days
1.0M
EPS TTM
$0.88
Shares Outstanding
232.3M
EX-Date
--
P/E TM
28.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for QIAGEN N.V. (QGEN)

qiagen n.v. (QGEN) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QGEN) Details

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. It offers approximately 500 core consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company’s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test, a test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non-cGMP DNA production on a contract basis. In addition, the company provides instrumentation systems that automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, and target detection, as well as workflow solutions. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation; and ESE-Quant Tube Scanners, an optical measurement device. The company serves molecular diagnostics laboratories; applied testing customers; pharmaceutical research and development groups, and academic researchers. It has a collaboration agreement with AstraZeneca PLC for the co-development and commercialization of a liquid biopsy-based companion diagnostic. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,000 Employees
Last Reported Date: 05/8/14
Founded in 1986

qiagen n.v. (QGEN) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: $1.5M
Chief Financial Officer, Managing Director an...
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

qiagen n.v. (QGEN) Key Developments

Qiagen NV to Partner with Astrazeneca

Qiagen NV has entered into a collaboration agreement with AstraZeneca PLC for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer (NSCLC). The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumour tissue is not available. QIAGEN and AstraZeneca will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study (IRESSA Follow-up Measure) presented at the World Lung 2013 conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood /plasma samples. This provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.

Qiagen NV Announces Launch of 14 New GeneRead DNAseq V2 Gene Panels

Qiagen NV announced the launch of 14 new GeneRead(TM) DNAseq V2 gene panels targeting an extensive range of cancer-related genes or gene regions. Gene panels are an integral part of many next-generation sequencing (NGS) workflows. They are used to enrich genes of interest in a sample prior to sequencing runs and as such can be seen as the core assay in the workflow. QIAGEN's new GeneRead panels are customizable to include other genes or gene regions of clinical or biological interest and are compatible with any NGS sequencer. They are part of QIAGEN's sample-to-library workflows, which are helping to drive the growing use of NGS in clinical applications. The 14 new GeneRead DNAseq V2 panels cover an extensive range of cancer-related genes and gene regions, including "focused" panels each targeting 8-25 genes, "disease-specific" panels for 40-50 genes, and "comprehensive" panels for as many as 160 genes. The content of the panels has been developed based on the new recommendations from relevant medical and scientific literature. The gene panels are integrated with QIAGEN's bioinformatics software, Ingenuity(R) Variant Analysis(TM), an extensive, curated database of gene variants and clinical data that enables interpretation of NGS results and delivers valuable insights from sequencing data. Laboratories also can customize GeneRead panels for specific disease pathways or research needs by tapping into QIAGEN's deep molecular content portfolio through GeneGlobe, an online portal covering more than 60,000 annotated molecular assays. QIAGEN has been collaborating with selected customers in the development of the new gene panels to validate product performance in a wide range of applications, including translational research and clinical applications. QIAGEN's GeneRead technology provides the most cost-effective, time-efficient approach for target enrichment in preparation for NGS runs on any sequencer. Unlike other approaches for sequencers, GeneRead panels use as little as 10 nanograms of starting DNA material per pool. They are compatible with FFPE samples and do not require any specialized instruments. The proprietary algorithms and chemistry provide coverage (>96% of coding regions), specificity (>90% of reads on target) and uniformity (>90% of bases are covered by at least 20% of the mean coverage depth) for the targeted DNA sequencing. In addition to their quality advantages, QIAGEN gene panels require only three hours to enrich for targets and provide for a substantially reduced time to go from isolated DNA sample to sequencing-ready libraries. QIAGEN provides a full range of sample technologies, assay panels and library preparation products which generate substantial revenue and solve important NGS needs in clinical and clinical research applications in particular. QIAGEN also is developing the benchtop GeneReader(TM) NGS platform for the same applications. Combined with QIAGEN's existing NGS portfolio, GeneReader is designed to provide a seamless automated workflow from biological sample, through DNA preparation, enrichment, library preparation, sequencing, data analysis and interpretation, to deliver valuable insights into diseases.

Qiagen NV to Report Q2, 2014 Results on Jul 29, 2014

Qiagen NV announced that they will report Q2, 2014 results on Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QGEN:US $25.18 USD +0.27

QGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $116.43 USD -1.22
BioMerieux €77.50 EUR +0.49
Hologic Inc $25.53 USD -0.35
Myriad Genetics Inc $37.05 USD +0.94
PerkinElmer Inc $47.15 USD -0.23
View Industry Companies
 

Industry Analysis

QGEN

Industry Average

Valuation QGEN Industry Range
Price/Earnings 100.0x
Price/Sales 4.4x
Price/Book 2.1x
Price/Cash Flow 118.2x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.